Biotech
Ottimo Pharma
Ottimo Pharma raises $140M Series A at $600M valuation
$140M
Total Raised
Series A
Latest Round
2024
Founded
60+
Employees
San Francisco, CA
1 min read
Quick Facts
Valuation
$600M
Latest Round Size
$140M
Latest Round Date
December 2024
Ottimo Pharma: Series A Funding Round
Ottimo Pharma has successfully raised $140M in Series A funding, reaching a valuation of $600M.
Company Overview
Developing biosimilar cancer treatment to compete with Keytruda
Funding Details
The Series A round was led by OrbiMed, with participation from Avoro Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2024
- Employees: 60+
- Category: Biotech
Investment
Ottimo Pharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- OrbiMed: Verified investor in Series A
- Avoro Capital: Verified investor in Series A
Key Investors
OrbiMed
Lead Investor
Verified investor in Series A
Avoro Capital
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M